undamentalytics Newsletter
Sign in

Lucid Diagnostics Inc. (LUCD) stock

Add to watchlist

Add holding +

NASDAQ: LUCD Nasdaq Health Care Equipment Next results ~November 12, 2026

D Fundamentals grade

Lucid Diagnostics Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.1

Forward price-to-sales vs peers

Base case. Range ~$0.1–$0.4. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Lucid Diagnostics Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds84 adding, 23 cuttingOf 15 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Lucid Diagnostics files

Where Lucid Diagnostics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $5m, up 24.9% on a year earlier, faster than the 23.0% growth a quarter earlier. Free-cash-flow margin rose to -876.8% from -1007.8% a year earlier. Operating margin widened to -930.9% from -1099.5%. The diluted share count is up 103.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Lucid Diagnostics Inc.'s trailing-twelve-month revenue grew 24.9% year on year, with a free-cash-flow margin of -876.8%. Where it lags: change in share count of 103.6% ranks 112 of 115 health care equipment companies we cover.

Current signal Operating margin expanding: TTM operating margin reached -930.9%, up 168.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 24.9% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 168.7 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -930.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -876.8% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 101.4% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 103.6% in a year.
  • High sales multiple. The shares trade at 10 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
-$0.06 against an average estimate of -$0.06: missed by 9.1%
Revenue
$1m, up 26.7% on a year earlier
Share reaction
-1.6% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.06

Lucid Diagnostics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.2%
  • 1 week-19.0%
  • 1 month-35.2%
  • This year-62.8%
  • 1 year-66.4%
  • 5 years-95.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$5.4M
Operating margin
-930.9%
Net margin
-959.8%
EPS (TTM, diluted)
$-0.37

Growth

Revenue growth
+24.9%
Change in growth rate
+1.9 pts
Share count change
+103.6%

Cash

Free cash flow (TTM)
-$47.7M
FCF margin
-876.8%
Stock pay % of revenue
101.4%

Earnings

Last results
August 13, 2026
Next results (est.)
November 11, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Share issue
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lucid Diagnostics Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Lucid Diagnostics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.8 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 Left out: out of range vs price (0.15x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.4 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.1 ~$0.1–$0.4 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lucid Diagnostics Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$5.37$1.36$1.41$0.82$1.09$0.41
Market value$400m$98m$118m$83m$111m$57m
+ Net debt (− = net cash)−$54m−$22m−$5m−$4m$0$0
Enterprise value$346m$76m$113m$79m$111m$57m
Multiples
Price / sales n/mn/m48.5x19.0x23.6x10.5x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

17 /100

Weak moat

How hard Lucid Diagnostics's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -134.2% of total assets over 5 years.

  • Durability 10 / 20

    Operating margin has been a median -1172.8%; its worst year was -6967.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -1179.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $2m and EPS of −$0.06 (range −$0.06 to −$0.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.24 +43% $6m +34%
Next −$0.17 +32% $17m +165%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −4.6% on 90 days ago. In the last 30 days, 1 analyst raised Lucid Diagnostics Inc.'s forecast and 1 cut it.

Consensus EPS forecast Lucid Diagnostics Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.26 Current fiscal year, 60 days ago: −$0.24 Current fiscal year, 30 days ago: −$0.24 Current fiscal year, 7 days ago: −$0.24 Current fiscal year, Now: −$0.24 −$0.24 Next fiscal year, 90 days ago: −$0.17 Next fiscal year, 60 days ago: −$0.17 Next fiscal year, 30 days ago: −$0.17 Next fiscal year, 7 days ago: −$0.17 Next fiscal year, Now: −$0.17 −$0.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.26−$0.17
60 days ago −$0.24−$0.17
30 days ago −$0.24−$0.17
7 days ago −$0.24−$0.17
Now −$0.24−$0.17

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.06 −$0.06 −9.1%
Mar 2026 −$0.06 −$0.07 −10.5%
Dec 2025 −$0.09 −$0.10 −15.4%
Sept 2025 −$0.09 −$0.10 −15.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Lucid Diagnostics Inc.'s latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026235
  2. Sep 2026235
  3. Aug 2026235

Counts of recommendations published by analysts covering Lucid Diagnostics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.2%
of tradable shares
Days to cover
7.5
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
33%
of shares
Held by insiders
26.5%
of shares
Employees
82
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
LUCD−75%+4%−42%+33%−63%
Industry peers (median)−37%−9%−19%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
LUCD33%67%42%58%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
LUCD−78%−35%−56%−41%−78%
S&P 500−25%−10%−8%−19%−9%

Worst fall since October 14, 2021: 97% from October 14, 2021 to October 22, 2026. Getting back needed a 3485% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.33 – $1.47
From 52-week high
−72.4%
vs 50-day average
−42.3%
vs 200-day average
−60.2%
Volatility (1 year)
76%
Beta vs S&P 500
1.08

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±5.1%
After a week
4 up, 8 down
typical move ±5.0%
After a month
5 up, 7 down
typical move ±12.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −1.6% +0.5% −2.4% −20.4%
May 14, 2026 −2.8% −0.4% −2.0% −2.0%
March 26, 2026 −5.9% −3.5% −4.2% −10.9%
November 12, 2025 +2.9% −1.6% −1.9% +11.5%
August 13, 2025 −1.7% +0.4% +3.2% +3.2%
May 14, 2025 +3.4% +0.6% +11.8% +8.4%
March 25, 2025 +3.3% −1.0% −5.3% −11.3%
November 13, 2024 +1.0% −0.6% 0.0% −21.5%
August 12, 2024 +8.9% +1.7% +8.9% +5.2%
May 14, 2024 −5.4% +1.7% −4.2% −22.2%
November 14, 2023 +14.7% +2.2% +12.1% +15.5%
March 14, 2023 +9.9% +1.0% −4.3% −16.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Lucid Diagnostics Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Lucid Diagnostics Inc.
$0 $2M $4M $6M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.5M Revenue (TTM), FY23 Q4: $2.4M Revenue (TTM), FY24 Q1: $3M Revenue (TTM), FY24 Q2: $3.8M Revenue (TTM), FY24 Q3: $4.2M Revenue (TTM), FY24 Q4: $4.3M Revenue (TTM), FY25 Q1: $4.2M Revenue (TTM), FY25 Q2: $4.4M Revenue (TTM), FY25 Q3: $4.4M Revenue (TTM), FY25 Q4: $4.7M Revenue (TTM), FY26 Q1: $5.1M Revenue (TTM), FY26 Q2: $5.4M $5.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.5M
FY23 Q4 $2.4M
FY24 Q1 $3M
FY24 Q2 $3.8M
FY24 Q3 $4.2M
FY24 Q4 $4.3M
FY25 Q1 $4.2M
FY25 Q2 $4.4M
FY25 Q3 $4.4M
FY25 Q4 $4.7M
FY26 Q1 $5.1M
FY26 Q2 $5.4M
Revenue growth, TTM YoY Lucid Diagnostics Inc.
0% 200% 400% 600% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 165.5% Revenue growth, TTM YoY, FY23 Q4: 544.0% Revenue growth, TTM YoY, FY24 Q1: 370.5% Revenue growth, TTM YoY, FY24 Q2: 379.2% Revenue growth, TTM YoY, FY24 Q3: 179.3% Revenue growth, TTM YoY, FY24 Q4: 79.0% Revenue growth, TTM YoY, FY25 Q1: 39.9% Revenue growth, TTM YoY, FY25 Q2: 14.7% Revenue growth, TTM YoY, FY25 Q3: 5.0% Revenue growth, TTM YoY, FY25 Q4: 8.3% Revenue growth, TTM YoY, FY26 Q1: 23.0% Revenue growth, TTM YoY, FY26 Q2: 24.9% 24.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 165.5%
FY23 Q4 544.0%
FY24 Q1 370.5%
FY24 Q2 379.2%
FY24 Q3 179.3%
FY24 Q4 79.0%
FY25 Q1 39.9%
FY25 Q2 14.7%
FY25 Q3 5.0%
FY25 Q4 8.3%
FY26 Q1 23.0%
FY26 Q2 24.9%
Operating margin (TTM) Lucid Diagnostics Inc.
-4000% -3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -3466.9% Operating margin (TTM), FY23 Q4: -1996.8% Operating margin (TTM), FY24 Q1: -1507.1% Operating margin (TTM), FY24 Q2: -1172.8% Operating margin (TTM), FY24 Q3: -1077.4% Operating margin (TTM), FY24 Q4: -1059.7% Operating margin (TTM), FY25 Q1: -1144.2% Operating margin (TTM), FY25 Q2: -1099.5% Operating margin (TTM), FY25 Q3: -1091.3% Operating margin (TTM), FY25 Q4: -1054.8% Operating margin (TTM), FY26 Q1: -959.6% Operating margin (TTM), FY26 Q2: -930.9% -930.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -3466.9%
FY23 Q4 -1996.8%
FY24 Q1 -1507.1%
FY24 Q2 -1172.8%
FY24 Q3 -1077.4%
FY24 Q4 -1059.7%
FY25 Q1 -1144.2%
FY25 Q2 -1099.5%
FY25 Q3 -1091.3%
FY25 Q4 -1054.8%
FY26 Q1 -959.6%
FY26 Q2 -930.9%
FCF margin (TTM) Lucid Diagnostics Inc.
-2000% -1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -1972.1% FCF margin (TTM), FY23 Q4: -1454.5% FCF margin (TTM), FY24 Q1: -1364.3% FCF margin (TTM), FY24 Q2: -1179.9% FCF margin (TTM), FY24 Q3: -1093.9% FCF margin (TTM), FY24 Q4: -1042.5% FCF margin (TTM), FY25 Q1: -1075.5% FCF margin (TTM), FY25 Q2: -1007.8% FCF margin (TTM), FY25 Q3: -1015.3% FCF margin (TTM), FY25 Q4: -1006.3% FCF margin (TTM), FY26 Q1: -915.3% FCF margin (TTM), FY26 Q2: -876.8% -876.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -1972.1%
FY23 Q4 -1454.5%
FY24 Q1 -1364.3%
FY24 Q2 -1179.9%
FY24 Q3 -1093.9%
FY24 Q4 -1042.5%
FY25 Q1 -1075.5%
FY25 Q2 -1007.8%
FY25 Q3 -1015.3%
FY25 Q4 -1006.3%
FY26 Q1 -915.3%
FY26 Q2 -876.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 0 2 4 5 5
Gross profit 1 0 — −3 −2 —
EBITDA −27 −54 −46 −45 −49 −50
Operating income −27 −56 −48 −46 −50 −51
Net income −28 −56 −53 −46 −58 −52
Diluted EPS −$0.38 −$0.78 −$0.63 −$0.53 — −$0.37
Growth (year on year)
Revenue — −24.6% +544.0% +79.0% +8.3% +24.9%
Margins
Gross margin 100.0% 100.0% — −63.3% −41.7% —
EBITDA margin <−999% <−999% <−999% <−999% <−999% −914.8%
Operating margin <−999% <−999% <−999% <−999% <−999% −930.9%
Net margin <−999% <−999% <−999% <−999% <−999% −959.8%
Free-cash-flow margin <−999% <−999% — <−999% −992.0% −860.8%
Cash flow
Cash from operations −18 −30 −33 −44 −46 −47
Capital spending 1 3 — 0 0 0
Free cash flow −19 −33 — −44 −47 −47
Stock-based pay 9 14 6 4 4 6
Free cash flow after stock pay −28 −47 — −49 −51 −52
Balance sheet
Cash 54 22 19 22 — —
Total debt — 0 14 19 24 24
Net debt (negative = net cash) −54 −22 −5 −4 — —
Diluted shares 74m 72m 84m 101m 102m 141m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $39m
Short-term assets $37mLonger-term assets $2m
What it owes, and who funded it · $39m
Short-term liabilities $28mLonger-term liabilities $1mShareholders' equity $11m
  • Short-term assets cover short-term liabilities $37m of assets due within a year against $28m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $37m short-term assets against $503,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$51m against $18,000 of interest.

From Lucid Diagnostics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+103.6%
year over year
R&D spending
99.0%
of revenue
Days sales outstanding
73 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated LUCD NRXS BIAF MCTA BMRA INBS Median
Revenue, last 12 months $5m $5m $6m $5m $4m $4m $99m
Revenue growth, last 12 months 24.9% 65.2% −23.2% −22.7% −11.2% 38.1% 9.2%
Revenue growth, 3-year average 90.1% 25.6% −12.2% — −7.1% 39.0% 13.5%
Revenue growth, latest quarter 26.7% 115.7% 19.0% — −8.3% 178.9% 10.2%
Gross margin 2.1% 85.6% 2.7% 99.3% 0.9% 48.6% 61.2%
Operating margin −930.9% −144.5% −209.8% −0.6% −125.2% −297.8% −8.5%
Operating margin, 3-year average <−999% −249.7% −152.9% — −114.4% −325.8% −17.9%
Net margin −959.8% −144.4% −257.3% −0.5% −115.5% −294.9% −12.0%
Cash from operations / revenue −860.8% −105.7% −194.3% −25.3% −91.2% −283.0% −1.9%
Free-cash-flow margin −876.8% −105.7% −195.9% −32.4% −91.2% −285.9% −3.9%
Free-cash-flow margin, 3-year average <−999% −224.0% −131.0% — −79.7% — −7.0%
Stock pay / revenue 101.4% 9.2% 15.8% — 8.2% 4.3% 6.1%
Change in share count 103.6% 43.8% — 5.3% 26.7% 50.1% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 24.9% 9.1% 32 of 129
Change in growth rate Growth +1.9pp -0.6pp 32 of 129
Operating margin Profitability -930.9% -8.3% 121 of 132
Net margin Profitability -959.8% -12.0% 121 of 133
Free-cash-flow margin Cash generation -876.8% -3.4% 120 of 128
Stock pay as % of revenue Cash generation 101.4% 6.1% 115 of 123
Change in share count Balance sheet 103.6% 3.3% 112 of 115
Days sales outstanding Balance sheet 73 days 57 days 87 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$65.7M
Institutions reporting
116
Shares held vs prior quarter
▲ 72.4%
Positions opened / closed
25 / 10

Top buyers and sellers, Q2 2026: 84 institutions bought and 23 sold ; the biggest buyer was Alyeska Investment Group, L.P (+8.9M shares) and the biggest seller Renaissance Technologies LLC (−428K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Alyeska Investment Group, L.P. $9.5M 8.9M 14.4% New
Blackrock, Inc. $9M 8.4M 13.6% ▲ 80.5%
Vanguard Capital Management LLC $7M 6.6M 10.7% ▲ 57.8%
Two Seas Capital LP $6.4M 6.0M 9.8% ▲ 100.0%
Masters Capital Management LLC $4.3M 4.0M 6.5% 0.0%
Aberdeen Group PLC $4.1M 3.8M 6.2% ▲ 4.9%
Geode Capital Management, LLC $4.1M 3.8M 6.2% ▲ 68.8%
State Street Corp $2.6M 2.4M 4.0% ▲ 56.8%
First Manhattan Co. Llc. $2.3M 2.2M 3.6% ▲ 576.6%
Wells Fargo & Company $2.2M 2.1M 3.4% ▲ 62.2%
Russell Investments Group, Ltd. $1.8M 1.7M 2.7% ▲ 4.3%
Northern Trust Corp $1.3M 1.2M 2.0% ▲ 81.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lucid Diagnostics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $245,000 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $245,000 net buying
Insider Date Trade Shares Price Value
Matheis Dennis Director May 20, 2026 Buy 245,000 $1.00 $245,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 26, 2026
  • November 12, 2025
  • August 13, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Lucid Diagnostics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lucid Diagnostics Inc. in brief

What does Lucid Diagnostics Inc. do?
Lucid Diagnostics Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Lucid Diagnostics Inc.'s stock ticker?
Lucid Diagnostics Inc. trades under the ticker LUCD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Lucid Diagnostics Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Lucid Diagnostics Inc. reported revenue of $5.4M, 24.9% higher than a year earlier, according to its SEC filings.
What is Lucid Diagnostics Inc.'s free cash flow?
Lucid Diagnostics Inc.'s free-cash-flow margin is -876.8% of revenue over the trailing twelve months, ranking 120 of the 128 health care equipment companies we cover.
Who are Lucid Diagnostics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Alyeska Investment Group, L.P., Blackrock, Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Lucid Diagnostics Inc.'s market cap?
On November 2, 2026, Lucid Diagnostics Inc.'s market capitalisation was about $57.2M and net debt of $0. Market figures come from third-party market data and may be delayed.
Who are Lucid Diagnostics Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Lucid Diagnostics Inc. are Neuraxis, Inc, Bioaffinity Technologies, Inc., Charming Medical Ltd, Biomerica Inc and Intelligent BIO Solutions Inc. The side-by-side comparison below sets their revenue, margins and growth against Lucid Diagnostics Inc.'s.
Are insiders buying or selling Lucid Diagnostics Inc. stock?
Over the last 12 months, Lucid Diagnostics Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Lucid Diagnostics Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lucid Diagnostics Inc. announces its own schedule.